title: Neurosteroids enhance the viability of staurosporine and doxorubicin treated differentiated human neuroblastoma SH-SY5Y cells.
abstract: Previously, we found that neurosteroids inhibited hydrogen peroxide- and staurosporine-induced damage of undifferentiated human neuroblastoma SH-SY5Y cells. However, differentiated neuroblastoma cells morphologically and functionally resemble neuronal cells, and are thus considered to be a model system for studying neuronal apoptotic processes. In the present study, we examined the effects of dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), and pregnenolone (PGL) on the viability of retinoic acid-differentiated human neuroblastoma SH-SY5Y cells. Mitochondrial and extracellular apoptotic processes in these cells were induced by staurosporine and doxorubicin, respectively. Calcein viability assays showed that doxorubicin (0.5 microM for 24 h) decreased cell viability by ca. 20% as compared to control cultures. DHEA and DHEAS at 0.1 and 1 microM concentrations, respectively, significantly inhibited the doxorubicin toxicity. PGL showed a neuroprotective effect only at 0.1 microM, whereas it was inactive at a higher concentration (1 microM). Staurosporine (1 microM for 24 h) decreased SH-SY5Y cell viability by ca. 50%. DHEA (0.1 and 1 microM) and DHEAS (0.1 and 1 microM) significantly antagonized the toxic effects of staurosporine, whereas these compounds showed no activity at the lowest concentration (0.01 microM). PGL inhibited the staurosporine-induced decrease in cell viability only at the concentration of 0.1 microM. Since staurosporine generated a stronger detrimental effect on SH-SY5Y cell viability than doxorubicin, we studied the mechanisms of neurosteroid action only in the former model. Staurosporine (1 microM for 24 h) enhanced lactate dehydrogenase (LDH) release by ca. 40% and this effect was inhibited by DHEA (0.01, 0.1, and 1 microM), DHEAS (0.1 and 1 microM) and PGL (0.01 and 01 microM). In order to verify an involvement of phosphatidylinositol-3-kinase (PI3-K) in the antiapoptotic action of neurosteroids, a specific inhibitor of this protein kinase (LY294002 at 10 microM) was used. Pretreatment of the cells with LY294002 antagonized the ameliorating effects of DHEA, DHEAS, and PGL on staurosporine-induced LDH release. These data indicated that at physiological concentrations, DHEA, DHEAS, and PGL prevented RA-differentiated SH-SY5Y cell damage produced by activation of both mitochondrial and extracellular apoptotic pathways. Furthermore, this study confirmed that the neuroprotective effects of neurosteroids in a staurosporine model of cytotoxicity appeared to be dependent upon PI3-K activity.
authors.affiliation: Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland. leskiew@if-pan.krakow.pl
authors.forename: Monika
authors.initials: M
authors.lastname: Leśkiewicz
authors.forename: Magdalena
authors.initials: M
authors.lastname: Regulska
authors.forename: Bogusława
authors.initials: B
authors.lastname: Budziszewska
authors.forename: Danuta
authors.initials: D
authors.lastname: Jantas
authors.forename: Lucylla
authors.initials: L
authors.lastname: Jaworska-Feil
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Basta-Kaim
authors.forename: Marta
authors.initials: M
authors.lastname: Kubera
authors.forename: Władysław
authors.initials: W
authors.lastname: Lasoń
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology*; D002273:Carcinogens / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002867:Chromones / Q000494:pharmacology; D003687:Dehydroepiandrosterone / Q000494:pharmacology; D019314:Dehydroepiandrosterone Sulfate / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005452:Fluoresceins; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000037:antagonists & inhibitors / Q000378:metabolism; D009025:Morpholines / Q000494:pharmacology; D009447:Neuroblastoma / Q000188:drug therapy / Q000473:pathology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011284:Pregnenolone / Q000494:pharmacology; D019311:Staurosporine / Q000494:pharmacology*; D013256:Steroids / Q000494:pharmacology*; D014212:Tretinoin / Q000494:pharmacology
chemical_list: D000903:Antibiotics, Antineoplastic; D002273:Carcinogens; D002867:Chromones; D004791:Enzyme Inhibitors; D005452:Fluoresceins; D009025:Morpholines; D013256:Steroids; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D003687:Dehydroepiandrosterone; D014212:Tretinoin; D019314:Dehydroepiandrosterone Sulfate; D011284:Pregnenolone; D004317:Doxorubicin; D007770:L-Lactate Dehydrogenase; D019869:Phosphatidylinositol 3-Kinases; D019311:Staurosporine; C007740:fluorexon